Expanding affordable access to innovative drugs will play a central role in addressing current and future global health challenges. This is particularly critical for low and middle-income economies as they look to reduce disease burdens through innovative medicines and strengthen healthcare delivery. Is there a policy framework that would both incentivise life sciences companies to continue risk-taking investments into the research of transformative cures — and make these cures available to patients who can least afford but most need access to them?
This discussion will seek to brainstorm and rebuild on best practice policies — including the convergence of intellectual property rights, voluntary licensing and strengthening healthcare infrastructure.
10:30 ‒ 11:00 a.m. | Registration
11:00 a.m. ‒ 11:10 a.m. | Opening Remarks
11:10 ‒ 11:30 a.m. | Keynote Address 11:30 ‒ 12:30 p.m. | Panel Discussion 12:30 ‒ 1:00 p.m. | Moderated Q&A1:00 ‒ 2:00 p.m. | Lunch
